Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study
Objective: To compare time to onset and magnitude of motor improvement following administration of apomorphine sublingual film (APL-130277; APL) vs levodopa in patients with Parkinson’s…Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease
Objective: This series of preclinical studies of novel levodopa and carbidopa/levodopa powder formulations delivered by the POD device to rats and non-human primates (NHP) guided…Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease
Objective: To describe correlations of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores with the 39-item Parkinson’s disease (PD) questionnaire…Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens
Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…Ambulatory monitoring of electrodermal activity (EDA) and Heart Rate Variability (HRV) for prediction of motor fluctuations in Parkinson’s Disease (PD)
Objective: To determine whether changes in EDA and HRV are associated with motor fluctuations in patients with PD Background: EDA and HRV are affected in…A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1
Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease
Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2
Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis
Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews
Objective: Identify symptoms and impacts associated with OFF-episodes (OEs). Background: OFF-episodes are commonly experienced in patients with Parkinson’s disease (PD). Qualitative research into patients’ experience…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 24
- Next Page »